Margaret M Harnett

Summary

Country: UK

Publications

  1. Doonan J, Tarafdar A, Pineda M, Lumb F, Crowe J, Khan A, et al. The parasitic worm product ES-62 normalises the gut microbiota bone marrow axis in inflammatory arthritis. Nat Commun. 2019;10:1554 pubmed publisher
  2. Doonan J, Thomas D, Wong M, Ramage H, Al Riyami L, Lumb F, et al. Failure of the Anti-Inflammatory Parasitic Worm Product ES-62 to Provide Protection in Mouse Models of Type I Diabetes, Multiple Sclerosis, and Inflammatory Bowel Disease. Molecules. 2018;23: pubmed publisher
    ..We speculate on the reasons underlying ES-62's failures in these conditions and how the negative data generated may help us to further understand ES-62's mechanism of action. ..
  3. Rzepecka J, Pineda M, Al Riyami L, Rodgers D, Huggan J, Lumb F, et al. Prophylactic and therapeutic treatment with a synthetic analogue of a parasitic worm product prevents experimental arthritis and inhibits IL-1β production via NRF2-mediated counter-regulation of the inflammasome. J Autoimmun. 2015;60:59-73 pubmed publisher
    ..Collectively, these data suggest that SMA-12b could provide the basis of an entirely novel approach to fulfilling the urgent need for new treatments for RA. ..
  4. Rodgers D, Pineda M, Suckling C, Harnett W, Harnett M. Drug-like analogues of the parasitic worm-derived immunomodulator ES-62 are therapeutic in the MRL/Lpr model of systemic lupus erythematosus. Lupus. 2015;24:1437-42 pubmed publisher
  5. Suckling C, Alam S, Olson M, Saikh K, Harnett M, Harnett W. Small Molecule Analogues of the parasitic worm product ES-62 interact with the TIR domain of MyD88 to inhibit pro-inflammatory signalling. Sci Rep. 2018;8:2123 pubmed publisher
    ..Thus, these new data identify initial events by which drug-like ES-62 SMAs, which we also demonstrate are able to inhibit cytokine production by human cells, homeostatically maintain "safe" levels of MyD88 signalling. ..
  6. Ball D, Al Riyami L, Harnett W, Harnett M. IL-33/ST2 signalling and crosstalk with FcεRI and TLR4 is targeted by the parasitic worm product, ES-62. Sci Rep. 2018;8:4497 pubmed publisher
  7. Latre De Late P, Pineda M, Harnett M, Harnett W, Besteiro S, Langsley G. Apicomplexan autophagy and modulation of autophagy in parasite-infected host cells. Biomed J. 2017;40:23-30 pubmed publisher
    ..In this mini-review, we summarise current knowledge on autophagy in both parasites and their host cells, in the context of infection by three Apicomplexa: Plasmodium, Toxoplasma, and Theileria. ..
  8. Harnett M, Pineda M, Latre De Late P, Eason R, Besteiro S, Harnett W, et al. From Christian de Duve to Yoshinori Ohsumi: More to autophagy than just dining at home. Biomed J. 2017;40:9-22 pubmed publisher
  9. Lumb F, Doonan J, Bell K, Pineda M, Corbet M, Suckling C, et al. Dendritic cells provide a therapeutic target for synthetic small molecule analogues of the parasitic worm product, ES-62. Sci Rep. 2017;7:1704 pubmed publisher
    ..Collectively, these studies indicate that drug-like compounds that target DCs can be designed from parasitic worm products and demonstrate the potential for ES-62 SMA-based DC therapy in inflammatory disease. ..

More Information

Publications10

  1. Harnett M, Harnett W. Can Parasitic Worms Cure the Modern World's Ills?. Trends Parasitol. 2017;33:694-705 pubmed publisher